Abstract:
BACKGROUND:Precore stop codon (G1896A) mutation is one of the commonest mutations found in patients with chronic hepatitis B. However, over the years, this mutation was not reported much in Malaysia. OBJECTIVES:We therefore investigated the presence of G1896A mutation in Malaysian population and its association with HBeAg status, clinical stage, hepatitis B virus (HBV) genotype and e-seroconversion rate. PATIENTS AND METHODS:Serum samples from 93 patients confirmed as hepatitis B carriers were collected for molecular assay. The whole genome of HBV was amplified by polymerase chain reaction and directly sequenced. The precore and basal core promoter regions were analyzed for presence of mutations. RESULTS:The most commonly observed mutation in the precore region was C1858T with 64.5% prevalence. The precore mutation of interest (G1896A) was identified in 25.8% of isolates. The basal core promoter mutations detected were A1762T-G1764A (26.9%), C1653T (8.6%), A1752G (10.8%) and C1766T (2.2%). No significant association was observed between G1896A mutation and HBeAg-negativity. Nonetheless, G1896A was highly prevalent among HBV genotype B. Clinical association revealed that subjects with G1896A mutations were mainly detected in asymptomatic chronic hepatitis B (58.3%) and liver cirrhosis (41.7%). One subject was diagnosed with fulminant hepatitis (4.2%) and 8.3% had hepatocellular carcinoma (HCC). CONCLUSIONS:Our data suggested an intermediate prevalence of G1896A mutation among Malaysian hepatitis B carriers. The stop codon mutation has a significant association with genotype B and patients with chronic hepatitis B and liver cirrhosis.
journal_name
Hepat Monjournal_title
Hepatitis monthlyauthors
Suppiah J,Mohd Zain R,Bahari N,Haji Nawi S,Saat Zdoi
10.5812/hepatmon.31490subject
Has Abstractpub_date
2015-10-28 00:00:00pages
e31490issue
10eissn
1735-143Xissn
1735-3408journal_volume
15pub_type
杂志文章abstract::Patients with chronic hepatitis B infection should be followed up to identify possible changes in disease status, such as HBsAg seronversion. There are little data on the outcome of such cases, and the response rate to HBV vaccine has not been discussed extensively. ...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:
更新日期:2011-02-01 00:00:00
abstract:BACKGROUND:Zinc deficiency has been reported frequently in hepatitis C patients in the literature. Furthermore, a decrease in zinc level has been shown in beta thalassemia major as well. Iranians consume a large amount of phytate in their regimens which can bind with zinc and decrease its gastrointestinal absorption. ...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.11138
更新日期:2013-08-12 00:00:00
abstract:BACKGROUND:Human leukocyte antigen (HLA) typing in autoimmune hepatitis (AIH) has been investigated in different populations and ethnic groups, but no such data is available from Pakistan. OBJECTIVES:The aim of this study was to evaluate the clinical profile of autoimmune hepatitis (AIH), and determine the associated ...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.13598
更新日期:2013-12-16 00:00:00
abstract:BACKGROUND:There are limited data on the prevalence of the hepatitis B virus (HBV) infection in the agricultural population worldwide. OBJECTIVES:This study aimed to determine the prevalence of HBV infection and associated risk factors in the reproductive-age female farmworker. MATERIALS AND METHODS:This cross-sectio...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.22120
更新日期:2014-11-23 00:00:00
abstract:BACKGROUND:Interleukin-10 (IL-10) is an important anti-inflammatory cytokine. The polymorphisms of its promoter gene have been considered to be related with the chronicity of hepatitis B infection. OBJECTIVES:The aim of this study was to evaluate the polymorphisms at different positions in the IL-10 promoter gene in p...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.28287v2
更新日期:2015-07-22 00:00:00
abstract:BACKGROUND AND AIMS:The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after hepatitis B virus (HBV) vaccination in order to determine the necessity of a singl...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:Hepatitis B is a common infectious disease in China. Many studies have shown that the genotype of hepatitis B virus (HBV) is probably associated with the efficacy of some antiviral drugs such as interferon α (IFN-α) and Lamivudine (LAM). However, the association between HBV genotype and adefovir dipivoxil (A...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.10813
更新日期:2014-08-17 00:00:00
abstract:BACKGROUND:Treatment of hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin (RBV) is associated with adverse events, which may affect the patient's adherence to the treatment regimen and the treatment efficacy. OBJECTIVES:The aim of this study was to assess the sustained viral response (SVR) and inte...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/kowsar.1735143X.789
更新日期:2011-12-01 00:00:00
abstract:CONTEXT:Hepatitis B vaccination of hemodialysis patients is performed all over the world. There are also recommendations from world health organizations to vaccinate patients with chronic kidney disease (CKD) prior dialysis commencement, but the implementation of a hepatitis B vaccination program is less common and not...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.7359
更新日期:2012-11-01 00:00:00
abstract:BACKGROUND:While Roux-en-Y hepaticojejunostomy (RYH) is the common anastomotic technique for liver transplantation (LT) in patients with primary sclerosing cholangitis (PSC), duct-to-duct (DD) reconstruction may be used if the recipient common bile duct is normal. There are conflicting observational data on the rate of...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.15(5)2015.18811
更新日期:2015-05-23 00:00:00
abstract:BACKGROUND:There are surprisingly a few studies that evaluate the impact of chronic viral hepatitis, which is common in HD (hemodialysis) patients, on HRQOL (health related quality of life). OBJECTIVES:We conducted a study to evaluate the impact of chronic viral hepatitis on HRQOL and to compare their HRQOL with non-i...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.9611
更新日期:2013-05-30 00:00:00
abstract:BACKGROUND:Good knowledge, attitude and practice (KAP) of the physicians allow them to handle their patients in such a way that they prevent themselves from contracting, and their patients from spreading, the infection. However, the Iranian standardized KAP questionnaire of physicians about viral hepatitis is not avail...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.7650
更新日期:2012-12-01 00:00:00
abstract:BACKGROUND:Approximately 5% of hepatitis B virus (HBV) carriers are coinfected with hepatitis D virus (HDV). HBV/HDV coinfection is a major cause of cirrhosis and end stage liver disease in chronic HBsAg carriers. The only approved therapy for chronic hepatitis delta is interferon alpha (IFN α) in either pegylated or c...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.15729
更新日期:2014-03-01 00:00:00
abstract:BACKGROUND:Current guidelines introduce periodic monitoring of serum alanine transaminase (ALT) as the first-line modality in follow-up patients, with a hepatitis B virus (HBV) inactive carrier state. OBJECTIVES:This study aimed to determine the incidence rate and patterns of ALT fluctuations and prognostic values for...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.17537
更新日期:2014-05-01 00:00:00
abstract:BACKGROUND:The hepatitis B virus (HBV) antigen-induced cellular immune response plays an important role in HBV clearance. Changes in the diversity of complementarity determining region 3 (CDR3) and T-cell receptor (TCR) sequences are used to monitor the response of T cells to antigens. OBJECTIVES:The aim of the presen...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.15900
更新日期:2014-02-25 00:00:00
abstract:BACKGROUND:GB virus C (GBV-C) or hepatitis G virus (HGV) is a newly discovered and enveloped RNA positive-stranded flavivirus-like particle, which has not yet been proven to have major negative effects on liver. OBJECTIVES:Increasing the risk of blood-borne infections in hemodialysis patients is a main health care con...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.18322
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Reversibility of advanced fibrosis after HCV-clearance is an important goal of therapy. OBJECTIVES:Measuring liver stiffness (LS) by transient elastography (TE) might be helpful in this setting. PATIENTS AND METHODS:We evaluated 104 patients with biopsy-proven chronic hepatitis C (CHC) and sustained virolo...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.7176
更新日期:2013-05-11 00:00:00
abstract:BACKGROUND:Infection with the hepatitis B virus (HBV) is an important global health problem. Knowledge of the geographic distribution pattern of HBV infection can help to control the spread of the disease. OBJECTIVES:To determine the prevalence of HBV infections and risk factors for the disease for the first time in B...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.36452
更新日期:2016-08-14 00:00:00
abstract:BACKGROUND:Hepatitis C virus infection is one of the leading causes of end stage liver diseases. The innate immune response slows down viral replication by activating cytokines such as type I interferon (IFN-α/β), which trigger the synthesis of antiviral proteins and modulate the adaptive immune system. Recently, leuci...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.15(5)2015.28473
更新日期:2015-05-23 00:00:00
abstract:BACKGROUND:Non-invasive methods for assessment of hepatic fibrosis are increasingly needed. Recent studies showed that combined elevation of tumor markers CA 19-9 and CA 125 is predictive of severe hepatic fibrosis or cirrhosis with high specificity. OBJECTIVES:We aimed at developing a new panel of surrogate biomarker...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.10810
更新日期:2013-06-16 00:00:00
abstract:CONTEXT:We briefly reviewed the evidence on the association of hepatitis C (HCV) infection with several aspects of mental and psychosocial health. EVIDENCE ACQUISITION:Medline was searched with appropriate keywords. The primary sources were the systematic reviews. If systematic reviews were not available for a subject...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.8340
更新日期:2013-01-01 00:00:00
abstract:BACKGROUND:About 30% of individuals with hepatitis C virus (HCV) infection are able to clear HCV spontaneously. Differences in host genetics affect the outcome of HCV infection. Single nucleotide polymorphisms (SNPs) of the Interferon lambda (IFNL) genes were associated with spontaneous and treatment-induced clearance ...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.22649
更新日期:2014-10-01 00:00:00
abstract:CONTEXT:The hepatitis C virus (HCV) is classified into seven genotypes and more than 100 subtypes. The treatment regimen, duration and efficacy of HCV therapy may vary according to the HCV genotype. Therefore, the HCV genotype should be determined prior to antiviral therapy. The objective of the current study was to re...
journal_title:Hepatitis monthly
pub_type: 杂志文章,评审
doi:10.5812/hepatmon.40357
更新日期:2016-08-23 00:00:00
abstract:BACKGROUND:Hepatitis C virus (HCV) is able to down-regulate innate immune response. It is important to know the immune pathways that this virus interacts with. HCV non-structural protein 3 (NS3) plays an important role in this viral feature. HCV NS3 protein could affect the expression of antiviral protein such as viper...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.17822
更新日期:2014-06-08 00:00:00
abstract:BACKGROUND:In Iran, the number of injecting drug users (IDUs) has increased in recent years. The rates of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections among IDUs are reportedly high. OBJECTIVES:The purpose of this study was to assess factors correlated with HCV and HBV infections among IDUs in Tehran...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/kowsar.1735143X.806
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:Nearly 0.5% of Iranians are infected with HCV. Peginterferon-alpha-2a and Peginterferon-alpha-2b are the two available types of interferon for the treatment of hepatitis C. Comparing the results of these two treatments is still a challenge. OBJECTIVES:The aim of this study was to compare the results of Pegi...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.30780
更新日期:2015-09-29 00:00:00
abstract:BACKGROUND:The prevalence of newly-diagnosed cases of chronic hepatitis is decisive for the overall incidence rate of hepatitis B observed in Poland. OBJECTIVES:We aimed to determine the chronic hepatitis B incidence trends in Poland, taking into consideration the ages, genders, and environments of the patients. METH...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.32692
更新日期:2016-07-25 00:00:00
abstract:BACKGROUND:In spite of dozens of clinical trials to establish effective therapeutic and/or preventive vaccine to resolve HCV infection, no real vaccine has been proved to date. Genetic vaccines based on replication-defective adenoviruses have proved to elicit strong and long lasting T-cell responses against a number of...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.6130
更新日期:2012-08-01 00:00:00
abstract::Approximately 170 million people worldwide are chronically infected by hepatitis C virus (HCV), which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease. The benchmark therapy for untreated HCV patients is a combination of pegylated interferon-alpha (PEG-IFN) an...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:
更新日期:2011-04-01 00:00:00
abstract:BACKGROUND:Hepatitis C virus (HCV) infection as a worldwide health problem is associated with cirrhosis and hepatocellular carcinoma. With current treatment regimen, pegylated interferon (PEG-IFN) plus ribavirin, sustain virological response (SVR) is achieved in only 50% of infected individuals. In HCV infection, an in...
journal_title:Hepatitis monthly
pub_type: 杂志文章
doi:10.5812/hepatmon.14476
更新日期:2014-01-23 00:00:00